ArticleJournal of applied clinical medical physics2026
Reducing the dose delivered to major intracranial blood vessels in brain radiotherapy using spot-scanning proton arc therapy.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) patients have poor clinical prognoses, which may partially be explainable by correlations between radiation-induced killing of circulating blood cells (CBCs) and worse clinical outcomes. Proton radiotherapy is currently delivered via intensity-modulated proton therapy (IMPT), for which the target is irradiated from a few different angles. Spot-scanning proton arc therapy (SPArc), for which the target is irradiated from arc trajectories, is associated with dosimetric benefits, and the first SPArc treatments of head-and-neck cancer patients have now been reported. However, since SPArc increases the low-dose bath, concerns have been raised about potentially higher killing of CBC. PURPOSE: This study aims to evaluate and compare blood vessel dose and dose-averaged linear energy transfer (LET
methodsFor 10 GBM patients, patient-specific cerebrovasculature models were developed, and IMPT and SPArc treatment plans were created according to current clinical standards (IMPT
resultsWhile treatment plans maintained comparable target coverage, blood vessel sparing significantly reduced the mean dose to delineated blood vessels, with values of 6.5 ± 2.9 Gy(RBE) for IMPT
conclusionsImplementation of blood vessel sparing resulted in successful reductions in blood vessel dose metrics while preserving target coverage, and SPArc further reduced blood vessel dose metrics compared with IMPT, with the potential to reduce radiation-induced lymphopenia and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.